Entera Bio (ENTX) Receivables - Other (2017 - 2018)
Entera Bio (ENTX) posted quarterly Receivables - Other of $836000.0 for Q4 2018, up 359.34% year-on-year from $182000.0 in Q4 2017, and up 359.34% on a QoQ basis from $182000.0 in Q4 2017.
Entera Bio (ENTX) Receivables - Other (2017 - 2018) Analysis & Trends
Entera Bio (ENTX) has reported Receivables - Other for 2 consecutive years, with $836000.0 the latest figure, recorded in Q4 2018.
- Quarterly Receivables - Other rose 359.34% year-over-year to $836000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $836000.0 (up 359.34% YoY) and the FY2018 annual result came in at $836000.0, up 359.34% from the prior year.
- Receivables - Other climbed to $836000.0 in Q4 2018 per ENTX's latest filing, from $182000.0 in the prior quarter.
- Over the last five years, Receivables - Other for ENTX reached as high as $836000.0 in Q4 2018 and fell as low as $182000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Entera Bio | 186.78 Mn | 182.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 836,000.00 |
| Dec 31, 2018 | 836,000.00 |
| Dec 31, 2017 | 182,000.00 |
| Dec 31, 2017 | 182,000.00 |